… of 2 long-acting bronchodilators in a pressurized metered-dose inhaler (MDI) is novel (see …
Unfortunately, it is well documented that 5%-18% (ie, several million) of COPD and asthma …

… novel, once-daily long-acting β 2 -agonist in development for the treatment of chronic obstructive
pulmonary disease (COPD) and asthma … study investigated the bronchodilation, safety, …

… Long-acting bronchodilators are recommended as maintenance … in longer studies and with
active comparators is warranted to evaluate its potential as a novel treatment option in COPD. …

… COPD, the relation between mechanical factors and inflammation is supported by results
from studies of patients with asthma, … in COPD: a novel phenotype. PLoS One 2012;7:e37483. …

… of a long-acting β2-agonist (LABA), and a long-acting … , such as asthma and chronic obstructive
pulmonary disease (COPD). … therapeutic approaches in asthma and COPD. The synergy …

… program for a novel LAMA to treat patients with COPD. AZD9164 is a potent … asthma and
moderate to severe COPD and also to assess the ability of AZD/LAS to produce bronchodilation…

… Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel
… by patients with asthma and COPD. J Aerosol Med Pulm Drug Deliv 2008;21:321-8. 76. …

… Citation41 To date, vilanterol is only marketed in combination with other COPD/asthma …
Abediterol is a novel, long-acting β 2 agonist synthesized by medicinal chemists at Almirall. …

… therapy in chronic obstructive pulmonary disease. The ICS/… compared to single long-acting
bronchodilator therapy. The … patients on single long-acting bronchodilator therapy or LABA/…

… β 2 -agonists (LABAs) and anticholinergics (LAMAs) in COPD is uncertain. We assessed the
… a second long-acting bronchodilator in patients with COPD. We identified a cohort of COPD …